Inactive/Delisted stock (the company was acquired by Double Point Ventures)
Lumos Pharma Stock (NASDAQ:LUMO)
Previous Close
$4.34
52W Range
$1.37 - $4.58
50D Avg
$4.23
200D Avg
$3.10
Market Cap
$37.54M
Avg Vol (3M)
$102.98K
Beta
0.33
Div Yield
-
LUMO Company Profile
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.